CPDR is a program of the Uniformed Services University of the Health Sciences
and the Henry M. Jackson Foundation for the Advancement of Military Medicine

< Publications Archive

> 1994 Publications

11-20   21-23

 

1. GNRH agonists for the treatment of advanced prostate cancer: managed care implications.
Trotter J, Greenstein F, Hom R, McLeod DG, Moul JW, Reich P, and Smith B:
Med. Interface 7(7) supplement; 14-32, 1994.

 

2. People gaining bowel and bladder control. In: Guidelines and Recommendations for Two Models of Continence Care.
Moul, JW:
Multidisciplinary Incontinence Clinic Task Force, The Pelvic Health Center: Spartanburg, SC:
HIP, Inc, 9-24, 1994.

 

3. Oncogenes and tumor suppressor genes. Moul JW, Gaddipati J and Srivastava S. Molecular biology of prostate cancer.
Current Clinical Oncology: Prostate Cancer.
(Eds. Dawson, N.A. and Vogelzang, N.J.),
Wiley-Liss Publications, 19-46, 1994.

 

4. Treatment-Post-prostatectomy incontinence. In: Clinicians Desk Reference: Assessment, Treatment, and Management of Incontinence.
Moul JW: Spartanburg, SC:
HIP, Inc. 1994.

 

5. Prostatic cancer and BPH.
Moul JW:
Postgrad. Med. 96(1): 24-25, (letter) 1994.

 

6. For incontinence after prostatectomy, tap a diversity of treatments.
Moul JW:
Contemp. Urol., 6(4):78-88, 1994.

 

7. DNA ploidy in nonseminomatous germ cell testicular tumor.
Moul JW:
Urology, 44:151-152, (letter), 1994.

 

8. AUA Yesterday: James Claude Kimbrough: The Father of Modern U.S. Army Urology.
Moul JW:
Part I: AUA Today 6(12):8-10, 1993;
Part II: AUA Today 7(1):9-12, 1994.

 

9. An important goal of prostatectomy: Minimizing incontinence.
Moul JW:
Contemp. Urol., 6(3): 15-28, 1994.

 

10. Testicular cancer in blacks: a multicenter experience.
Moul JW, Schanne FJ, Thompson IM, Frazier HA, Peretsman SA, Wettlaufer JN, Rozanski TA, Stack RS, Kreder KJ, and Hoffman KJ:
Cancer 73:388-93, 1994.